Nathalie Heuzé-Vourc’h, INSERM - Qepler Summits And Conferences

Nathalie Heuzé-Vourc’h

Research Director
INSERM
Tours, France
Inserm - From science to health

Nathalie Heuzé-Vourc’h, Research Director at INSERM, the National Institute of Biomedical Research in France. She leads a multidisciplinary team in the Research Centre for Respiratory Diseases (CEPR, INSERM U1100) in Tours, dedicated to ‘Aerosoltherapy and Biotherapeutcs for Respiratory Diseases’ (team 3).

After graduating with her Ph.D. in oncology in France, she focused her research on lung diseases and obtained a postdoctoral position in the division of pulmonary and critical care medicine (Dr Steven M. Dubinett) at UCLA, California.

She gained interest in biotherapeutics working in a start-up (Agensys Inc., Santa Monica, California) developing anticancer monoclonal antibodies and was recruited in 2005 by INSERM as a young research scientist to continue working on this topic.

Joining Pr Patrice Diot’s research group specialized in the delivery of drugs by aerosol in Tours, offered her new perspectives on her research projects as she started investigating the local delivery of biotherapeutics through the airways.

She is currently supervising several projects on the multifaceted aspects of the delivery of biotherapeutics through the airways for treatments of lung diseases, from formulation to preclinical safety, with both academic and private partners. She has published more than 60 peer-reviewed papers and book chapters.

She is one of the leaders of the Laboratory of Excellence ’MabImprove’, since 2011, from the French program ‘Investments for the Future.’

She is the co-founder of Cynbiose Respiratory, a CRO specialized in experimental models in the respiratory field and serves regularly as a consultant to the pharma industry on aerosol therapy.

Related Sessions:

2nd Annual Inhaled
Drug Delivery Summit 2020

Assess and harness novel approaches to the development of inhaled drug products for enhanced patient care.
  • 17 Sep 2020
  • Prague, CZ
  • Pharma
Day 1: Thursday, 17 September 2020
CASE STUDY: Inhaled phage therapy as an alternative to antibiotics in respiratory tract infections.
  • bacteriophages
  • preclinical development of inhaled phage
  • nebulization of phage
View Details